Notes · Bioequivalence.

The feed of writing relevant to bioequivalence practice. ICH M13A, RSABE for highly variable drugs, the FDA-EMA divergence, biowaivers. Filtered from the global archive.

View global notes archive →

1 note on this domain · from a global archive of 13 View global archive →

2026-03-13

RSABE divergence post-ICH M13A: a practitioner's map.

The FDA-EMA divergence on highly variable drug scaling persists even with M13A in force. What sponsors filing in both regions still need to design around.

bioequivalenceICH M13ARSABE

~7 min

← Players & stakeholders Chapter 09 of 9 · Bioequivalence Overview →